Literature DB >> 20723637

Relation between infarct size in ST-segment elevation myocardial infarction treated successfully by percutaneous coronary intervention and left ventricular ejection fraction three months after the infarct.

Yuri B Pride1, Jennifer L Giuseffi, Satishkumar Mohanavelu, Caitlin J Harrigan, Warren J Manning, C Michael Gibson, Evan Appelbaum.   

Abstract

The goal of this analysis was to determine the relation between myocardial infarct size and left ventricular (LV) ejection fraction (EF) in patients with ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (pPCI) using cardiovascular magnetic resonance imaging (CMR). After STEMI, LVEF and infarct size correlate with prognosis, but the relation between infarct size and LVEF is incompletely known. Consecutive subjects presenting to a single center with STEMI treated with pPCI were enrolled, and cine functional and late gadolinium enhancement CMR was performed 3 months after presentation. From cine images, LVEF was calculated using volumetric summation of disks method. Infarct size was measured as percent LV myocardial volume with late gadolinium enhancement. In the 78 patients enrolled (mean age 54.5 years, range 42 to 82), median LVEF was 56% (interquartile range 49 to 62) and median infarct size was 11% (interquartile range 5 to 18). Of the 53 patients with infarct size <15%, all had LVEF >40%, and there was no significant relation between infarct size and LVEF (slope -0.43, R(2) = 0.045, p = 0.13). In patients with infarct size > or =15%, there was a significant negative linear association between infarct size and LVEF (slope -1.21, R(2) = 0.66, p <0.001), such that for every 5% increase in infarct size, there was a 6.1% decrease in LVEF. In conclusion, there is a negative linear relation between infarct size and LVEF for moderate to large infarcts. For small infarcts there is no significant relation between infarct size and LVEF. Up to 15% of LV myocardial volume may be infarcted before there is any appreciable decrease in LVEF. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20723637     DOI: 10.1016/j.amjcard.2010.04.012

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention.

Authors:  Roberto Sciagrà; Fabrizio Cipollini; Valentina Berti; Angela Migliorini; David Antoniucci; Alberto Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-10       Impact factor: 9.236

2.  Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction.

Authors:  Ronald Reiter; Cory Swingen; Luke Moore; Timothy D Henry; Jay H Traverse
Journal:  Circ Res       Date:  2011-11-17       Impact factor: 17.367

Review 3.  Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.

Authors:  Shi Yin Wong; Ainsley Ryan Yan Bin Lee; Aaron Hon Jiun Sia; Yu Jun Wo; Yao Hao Teo; Yao Neng Teo; Nicholas L Syn; Ching-Ching Ong; Lynette L Teo; Tiong-Cheng Yeo; Kian-Keong Poh; William K Kong; Raymond C Wong; Ching-Hui Sia
Journal:  Cardiovasc Drugs Ther       Date:  2022-07-12       Impact factor: 3.947

4.  Myocardial perfusion reserve in spared myocardium: correlation with infarct size and left ventricular ejection fraction.

Authors:  Luis Eduardo Juárez-Orozco; Julius Glauche; Erick Alexanderson; Clark J Zeebregts; Hendrikus H Boersma; Andor W J M Glaudemans; Rudi A Dierckx; Dirk J van Veldhuisen; René A Tio; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-04       Impact factor: 9.236

5.  Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.

Authors:  Raj R Makkar; Rachel R Smith; Ke Cheng; Konstantinos Malliaras; Louise Ej Thomson; Daniel Berman; Lawrence Sc Czer; Linda Marbán; Adam Mendizabal; Peter V Johnston; Stuart D Russell; Karl H Schuleri; Albert C Lardo; Gary Gerstenblith; Eduardo Marbán
Journal:  Lancet       Date:  2012-02-14       Impact factor: 79.321

6.  Metabolic Syndrome is Associated With Higher Wall Motion Score and Larger Infarct Size After Acute Myocardial Infarction.

Authors:  Shokoufeh Hajsadeghi; Mitra Chitsazan; Mandana Chitsazan; Majid Haghjoo; Nima Babaali; Zahra Norouzzadeh; Maryam Mohsenian
Journal:  Res Cardiovasc Med       Date:  2015-02-20

7.  Circadian Dependence of Infarct Size and Acute Heart Failure in ST Elevation Myocardial Infarction.

Authors:  Aruni Seneviratna; Gek Hsiang Lim; Anju Devi; Leonardo P Carvalho; Terrance Chua; Tian-Hai Koh; Huay-Cheem Tan; David Foo; Khim-Leng Tong; Hean-Yee Ong; A Mark Richards; Chow Khuan Yew; Mark Y Chan
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

8.  CTGF/CCN2 Postconditioning Increases Tolerance of Murine Hearts towards Ischemia-Reperfusion Injury.

Authors:  Ole Jørgen Kaasbøll; Ingvild Tronstad Moe; Mohammad Shakil Ahmed; Espen Stang; Else Marie Valbjørn Hagelin; Håvard Attramadal
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

9.  A hospital-wide system to ensure rapid treatment time across the entire spectrum of emergency percutaneous intervention.

Authors:  Umesh N Khot; Michele L Johnson-Wood; Robert VanLeeuwen; Curtis Ramsey; Monica B Khot
Journal:  Catheter Cardiovasc Interv       Date:  2015-12-23       Impact factor: 2.692

10.  Left ventricular reverse remodeling in patients with anterior wall ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Marek Grabka; Magdalena Kocierz-Woźnowska; Maciej Wybraniec; Maciej Turski; Marcin Wita; Krystian Wita; Katarzyna Mizia-Stec
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-12-11       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.